publication date: Sep. 15, 2017

In Brief Teitell named director of the UCLA Jonsson Comprehensive Cancer Center

Michael Teitell, a molecular immunologist and biochemist, was named director of the UCLA Jonsson Comprehensive Cancer Center and president of the Jonsson Cancer Center Foundation.

Teitell, who was chosen after a national search, has been a member of the faculty at the David Geffen School of Medicine at UCLA since 1999. He is the Latta Endowed Professor of Pathology and holds joint appointments in the departments of pediatrics and bioengineering. Also, he serves as chief of the Division of Pediatric and Neonatal Pathology.

Teitell will succeed Dr. Kenneth Dorshkind, who has served as interim director since 2014.

The Jonsson Comprehensive Cancer Center has more than 450 researchers and clinicians engaged in cancer research, prevention, detection, control, treatment and education. Its physicians and scientists handle more than 20,000 patient visits per year.

At UCLA, research in Teitell’s laboratory began with studies of fundamental mechanisms of cancer formation and progression, particularly for B lymphocyte malignancies. This led to projects in stem cell and cancer cell metabolism and the collaborative development of new approaches in cell engineering and response detection. The research lab has received continuous funding since 1999.

Teitell serves as co-director of the UCLA Tumor Immunology Training Program, co-director of the Broad Stem Cell Research Center Bioengineering Core, an associate director of the UCLA-Caltech Medical … Continue reading Teitell named director of the UCLA Jonsson Comprehensive Cancer Center

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.